Interaksi Klopidogrel

CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment [see Warnings and Precautions (5.7) , Drug Interactions (7.2) , and Clinical Pharmacology (12.2) ]. (label Abrositinib, Kontraindikasi)

…hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (label Apiksaban, Peringatan kotak hitam)

Antiplatelets: ticagrelor ↑ ticagrelor Coadministration with ticagrelor is not recommended due to potential increase in the risk of dyspnea, bleeding and other adverse events associated with ticagrelor. clopidogrel ↓ clopidogrel active metabolite Coadministration of REYATAZ (with or without ritonavir) and clopidogrel is not recommended. (label Atazanavir, Interaksi obat)

Coadministration of bupropion hydrochloride extended-release tablets (XL) with ticlopidine or clopidogrel is not recommended (7.1). (label Bupropion, Interaksi obat)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (label Dabigatran, Peringatan kotak hitam)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (label Edoksaban, Peringatan kotak hitam)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

Antiplatelets: ticagrelor ↑ ticagrelor Coadminstration with ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Coadministration with clopidogrel is not recommended due to protential reduction of the antiplatelet activity of clopidogrel. (label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir, Interaksi obat)

…hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between… (label Enoksaparin, Peringatan kotak hitam)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (label Klopidogrel, Peringatan dan perhatian)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (label Feri sitrat, Interaksi obat)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity or spinal surgery • Optimal timing between… (label Fondaparinuks, Peringatan kotak hitam)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

Anticoagulants and Antiplatelets Ticagrelor Contraindicated during and 2 weeks after TOLSURA treatment. (label Itrakonazol, Interaksi obat)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

Clopidogrel: Do not administer during KENGREAL infusion. (label Kangrelor, Interaksi obat)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (label Klopidogrel, Peringatan dan perhatian)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (label Klopidogrel, Peringatan dan perhatian)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (label Klopidogrel, Peringatan dan perhatian)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (label Klopidogrel, Peringatan dan perhatian)

Cardiovascular agents aliskiren, ticagrelor, vorapaxar clopidogrel ↑ aliskiren ↑ ticagrelor ↑ vorapaxar ↓ clopidogrel active metabolite Avoid concomitant use with PAXLOVID. cilostazol ↑ cilostazol Dosage adjustment of cilostazol is recommended. (label Nirmatrelvir dan ritonavir, Interaksi obat)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (label Klopidogrel, Peringatan dan perhatian)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (label Klopidogrel, Peringatan dan perhatian)

…TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Effient (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). (label Prasugrel, Kontraindikasi)

Avoid concomitant use of repaglinide with Plavix. (label Klopidogrel, Interaksi obat)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (label Klopidogrel, Peringatan dan perhatian)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (label Klopidogrel, Peringatan dan perhatian)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (label Rivaroksaban, Peringatan kotak hitam)

Celecoxib 100 mg twice daily was non-inferior to naproxen 375 to 500 mg twice daily and ibuprofen 600 to 800 mg three times daily for the composite endpoint of the Antiplatelet Trialists' Collaboration (APTC), which consists of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction, and non-fatal stroke [ see Clinical Studies (14.5)… (label Selekoksib, Peringatan dan perhatian)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

WARNING: BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). (label Tikagrelor, Peringatan kotak hitam)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (label Klopidogrel, Peringatan dan perhatian)

Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (label Alteplase, Interaksi obat)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (label Anagrelid, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (label Epoprostenol, Interaksi obat)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiplatelets Ticagrelor Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (label Fenitoin, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antiplatelets Ticagrelor Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (label Fosfenitoin, Interaksi obat)

Ginkgo mungkin meningkatkan risiko perdarahan bila digunakan bersama obat antikoagulan atau antiplatelet. (NCCIH, Ginkgo)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (label Ikosapen etil, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Anticoagulants and Antiplatelet Drugs rivaroxaban cilostazol, coumarins, dabigatran Cilostazol: Concomitant administration of single doses of cilostazol 100 mg and ketoconazole 400 mg approximately doubled cilostazol concentrations and altered (increase/decrease) the concentrations of the active metabolites of cilostazol. (label Ketokonazol, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Misoprostol does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. (label Misoprostol, Interaksi obat)

Consider the use of a parenteral antiplatelet agent in acute coronary syndrome patients requiring coadministration of morphine or other opioid agonists. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Concomitant Treatment with CYP2B6 Inhibitors (e.g., ticlopidine or clopidogrel) can increase bupropion exposure. (label Naltrekson dan bupropion, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (label Pentoksifilin, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Should serious bleeding that is not controlled by local pressure occur, discontinue any concomitant heparin or antiplatelet agents immediately and treat appropriately. (label Tenekteplase, Peringatan dan perhatian)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (label Klopidogrel, Interaksi obat)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (label Klopidogrel, Peringatan dan perhatian)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Opioids: Decreased exposure to clopidogrel. (label Klopidogrel, Interaksi obat)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (label Trazodon, Peringatan dan perhatian)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

Vitamin E dapat menghambat agregasi trombosit dan pembekuan darah yang bergantung pada vitamin K, sehingga meningkatkan risiko perdarahan dengan obat antikoagulan dan antiplatelet. (NIH Office of Dietary Supplements, Vitamin E)

• Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (label Vortioksetin, Peringatan dan perhatian)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

Suplemen bawang putih mungkin meningkatkan risiko perdarahan dengan antikoagulan seperti warfarin. (NCCIH, Garlic)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

If possible, assess the presence of drug-dependent antiplatelet antibodies. (label Etosuksimid, Peringatan)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

Suplemen omega-3 mungkin sedikit memperpanjang waktu perdarahan; kombinasi dengan antikoagulan seperti warfarin memerlukan pemantauan, meskipun perdarahan yang bermakna secara klinis belum terbukti secara konsisten. (NIH Office of Dietary Supplements, Omega-3 Fatty Acids)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (label Klopidogrel, Interaksi obat)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZISTA/ritonavir and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZISTA/ritonavir and clopidogrel is not recommended due to potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel active metabolite… (label Darunavir, Interaksi obat)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZCOBIX or PREZCOBIX PED and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZCOBIX or PREZCOBIX PED with clopidogrel is not recommended due to the potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel… (label Darunavir dan kobisistat, Interaksi obat)

Platelet Aggregation Inhibitors Clopidogrel: No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with nifedipine. (label Nifedipin, Interaksi obat)